Molecular targets of celastrol derived from Thunder of God Vine: Potential role in the treatment of inflammatory disorders and cancer

Cancer Letters

Volumn 303, Issue 1, 2011, Pages 9-20

  Kannaiyan, Radhamani ^a   Shanmugam, Muthu K ^a   Sethi, Gautam ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Angiogenesis; Cancer; Celastrol; Inflammatory disorders; Metastasis

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 NITROPROPIONIC ACID; 4 CARBOXYPHENYLGLYCINE; ACETYLCYSTEINE; BUTHIONINE SULFOXIMINE; CELASTROL; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CXCR4; DEATH RECEPTOR 4; DNA TOPOISOMERASE (ATP HYDROLYSING); DULANERMIN; GLUTAMIC ACID; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HEAT SHOCK PROTEIN; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAMMALIAN TARGET OF RAPAMYCIN; NOTCH1 RECEPTOR; POTASSIUM CHANNEL; PROTEIN KINASE B; PTERIN DERIVATIVE; SALAZOSULFAPYRIDINE; STRESS ACTIVATED PROTEIN KINASE; TRIPTERINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRITIS; ASTHMA; BONE METASTASIS; BREAST CANCER; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CHINESE MEDICINE; CROHN DISEASE; CYTOTOXICITY; DEGENERATIVE DISEASE; DRUG ANTAGONISM; DRUG PELLET; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; GLIOMA; HUMAN; HUNTINGTON CHOREA; HYPERTENSION; INFLAMMATION; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS INHIBITION; NONHUMAN; PANCREAS CANCER; PARKINSON DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; SHORT SURVEY; SIGNAL TRANSDUCTION; SKIN INFLAMMATION; SUSTAINED DRUG RELEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TRADITIONAL MEDICINE; TUMOR CELL;

ANIMALIA;

EID: 79951853010     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.10.025     Document Type: Review

References (116)

1. Gullett N.P., Ruhul Amin A.R., Bayraktar S., Pezzuto J.M., Shin D.M., Khuri F.R., Aggarwal B.B., Surh Y.J., Kucuk O. Cancer prevention with natural compounds. Semin. Oncol. 2010, 37:258-281.
2. Aggarwal B.B., Danda D., Gupta S., Gehlot P. Models for prevention and treatment of cancer: problems vs promises. Biochem. Pharmacol. 2009, 78:1083-1094.
3. Allavena P., Garlanda C., Borrello M.G., Sica A., Mantovani A. Pathways connecting inflammation and cancer. Curr. Opin. Genet. Dev. 2008, 18:3-10.
4. Mantovani A. Molecular pathways linking inflammation and cancer. Curr. Mol. Med. 2010, 10:369-373.
5. Aggarwal B.B., Shishodia S., Sandur S.K., Pandey M.K., Sethi G. Inflammation and cancer: how hot is the link?. Biochem. Pharmacol. 2006, 72:1605-1621.
6. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
7. Mantovani A. Cancer: inflaming metastasis. Nature 2009, 457:36-37.
8. Aggarwal B.B., Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients?. Curr. Opin. Pharmacol. 2009, 9:351-369.
9. Tao X., Younger J., Fan F.Z., Wang B., Lipsky P.E. Benefit of an extract of Tripterygium wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum. 2002, 46:1735-1743.
10. Sethi G., Kwang S.A., Pandey M.K., Aggarwal B.B. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-κB-regulated gene products and TAK1-mediated NF-κB activation. Blood 2007, 109:2727-2735.
11. Salminen A., Lehtonen M., Paimela T., Kaarniranta K. Celastrol: molecular targets of Thunder God Vine. Biochem. Biophys. Res. Commun. 2010, 394:439-442.
12. Sogno I., Vannini N., Lorusso G., Cammarota R., Noonan D.M., Generoso L., Sporn M.B., Albini A. Anti-angiogenic activity of a novel class of chemopreventive compounds: oleanic acid terpenoids. Recent Results Cancer Res. 2009, 181:209-212.
13. He M.F., Liu L., Ge W., Shaw P.C., Jiang R., Wu L.W., But P.P.H. Antiangiogenic activity of Tripterygium wilfordii and its terpenoids. J. Ethnopharmacol. 2009, 121:61-68.
14. Sethi G., Tergaonkar V. Potential pharmacological control of the NF-kappaB pathway. Trends Pharmacol. Sci. 2009, 30:313-321.
15. Zhang D., Xu L., Cao F., Wei T., Yang C., Uzan G., Peng B. Celastrol regulates multiple nuclear transcription factors belonging to HSP90's clients in a dose- and cell type-dependent way. Cell Stress Chaperones 2010, 1-8.
16. Zhu H., Ding W.J., Wu R., Weng Q.J., Lou J.S., Jin R.J., Lu W., Yang B., He Q.J. Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol. Cancer Invest. 2010, 28:23-32.
17. Zhu H., Liu X.W., Ding W.J., Xu D.Q., Zhao Y.C., Lu W., He Q.J., Yang B. Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L. Cancer Lett. 2010.
18. Sung B., Park B., Yadav V.R., Aggarwal B.B. Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors. J. Biol. Chem. 2010, 285:11498-11507.
19. Pang X., Yi Z., Zhang J., Lu B., Sung B., Qu W., Aggarwal B.B., Liu M. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res. 2010, 70:1951-1959.
20. Wu F., Han M., Wilson J.X. Tripterine prevents endothelial barrier dysfunction by inhibiting endogenous peroxynitrite formation. Br. J. Pharmacol. 2009, 157:1014-1023.
21. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
22. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
23. Balkwill F., Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin. Pharmacol. Ther. 2010, 87:401-406.
24. Hyo W.J., Yoo S.C., Yoon S.K., Park Y.K. Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-κB in LPS-stimulated BV-2 microglial cells. Exp. Mol. Med. 2007, 39:715-721.
25. Allison A.C., Cacabelos R., Lombardi V.R.M., Álvarez X.A., Vigo C. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Progr. Neuro-Psychopharmacol. Biol. Psychiat. 2001, 25:1341-1357.
26. Pinna G.F., Fiorucci M., Reimund J.M., Taquet N., Arondel Y., Muller C.D. Celastrol inhibits pro-inflammatory cytokine secretion in Crohn's disease biopsies. Biochem. Biophys. Res. Commun. 2004, 322:778-786.
27. Kim D.H., Shin E.K., Kim Y.H., Lee B.W., Jun J.G., Park J.H.Y., Kim J.K. Suppression of inflammatory responses by celastrol, a quinone methide triterpenoid isolated from Celastrus regelii. Eur. J. Clin. Invest. 2009, 39:819-827.
28. Nakamichi K., Kitani H., Takayama-Ito M., Morimoto K., Kurane I., Saijo M. Celastrol suppresses morphological and transcriptional responses in microglial cells upon stimulation with double-stranded RNA. Int. J. Neurosci. 2010, 120:252-257.
29. Huang F.C., Chan W.K., Moriarty K.J., Zhang D.C., Chang M.N., He W., Yu K.T., Zilberstein A. Novel cytokine release inhibitors. Part I: triterpenes. Bioorg. Med. Chem. Lett. 1998, 8:1883-1886.
30. Kim Y., Kim K., Lee H., Han S., Lee Y.S., Choe J., Kim Y.M., Hahn J.H., Ro J.Y., Jeoung D. Celastrol binds to ERK and inhibits FcεRI signaling to exert an anti-allergic effect. Eur. J. Pharmacol. 2009, 612:131-142.
31. Hui Z.J., Bang Y.H., Hang S.K., Jeong H.L., Young H.K., Jung J.L. Antiinflammatory constituents of Celastrus orbiculatus inhibit the NF-κB activation and NO production. J. Nat. Prod. 2002, 65:89-91.
32. Wang J., Gigliotti F., Bhagwat S.P., Maggirwar S.B., Wright T.W. Pneumocystis stimulates MCP-1 production by alveolar epithelial cells through a JNK-dependent mechanism. Am. J. Physiol. - Lung Cell. Mol. Physiol. 2007, 292:L1495-L1505.
33. Sassa H., Takaishi Y., Terada H. The triterpene celastrol as a very potent inhibitor of lipid peroxidation in mitochondria. Biochem. Biophys. Res. Commun. 1990, 172:890-897.
34. Sassa H., Kogure K., Takaishi Y., Terada H. Structural basis of potent antiperoxidation activity of the triterpene celastrol in mitochondria: effect of negative membrane surface charge on lipid peroxidation. Free Rad. Biol. Med. 1994, 17:201-207.
35. Zhang D.H., Marconi A., Xu L.M., Yang C.X., Sun G.W., Feng X.L., Ling C.Q., Qin W.Z., Uzan G., D'Alessio P. Tripterine inhibits the expression of adhesion molecules in activated endothelial cells. J. Leukocyte Biol. 2006, 80:309-319.
36. Abbas S., Bhoumik A., Dahl R., Vasile S., Krajewski S., Cosford N.D.P., Ronai Z.A. Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin. Cancer Res. 2007, 13:6769-6778.
37. Yu X., Tao W., Jiang F., Li C., Lin J., Liu C. Celastrol attenuates hypertension-induced inflammation and oxidative stress in vascular smooth muscle cells via induction of heme oxygenase-1. Am. J. Hypertens. 2010, 23:895-903.
38. Hu H., Straub A., Tian Z., Bassler N., Cheng J., Peter K. Celastrol, a triterpene extracted from Tripterygium wilfordii Hook F, inhibits platelet activation. J. Cardiovas. Pharmacol. 2009, 54:240-245.
39. Barker J.N.W.N., Sarma V., Mitra R.S., Dixit V.M., Nickoloff B.J. Marked synergism between tumor necrosis factor-α and interferon-γ in regulation of keratinocyte-derived adhesion molecules and chemotactic factors. J. Clin. Invest. 1990, 85:605-608.
40. Dustin M.L., Singer K.H., Tuck D.T., Springer T.A. Adhesion of T lymphoblasts to epidermal keratinocytes is regulated by interferon γ and is mediated by intercellular adhesion molecule 1 (ICAM-1). J. Exp. Med. 1988, 167:1323-1340.
41. Seo W.Y., Ju S.M., Song H.Y., Goh A.R., Jun J.G., Kang Y.H., Choi S.Y., Park J. Celastrol suppresses IFN-gamma-induced ICAM-1 expression and subsequent monocyte adhesiveness via the induction of heme oxygenase-1 in the HaCaT cells. Biochem. Biophys. Res. Commun. 2010, 398:140-145.
42. Hur G.Y., Sheen S.S., Kang Y.M., Koh D.H., Park H.J., Ye Y.M., Yim H.E., Kim K.S., Park H.S. Histamine release and inflammatory cell infiltration in airway mucosa in methylene diphenyl diisocyanate (MDI)-induced occupational asthma. J. Clin. Immunol. 2008, 28:571-580.
43. Zimmermann N., Hershey G.K., Foster P.S., Rothenberg M.E. Chemokines in asthma: cooperative interaction between chemokines and IL-13. J. Allergy Clin. Immunol. 2003, 111:227-243.
44. Broide D.H. Molecular and cellular mechanisms of allergic disease. J. Allergy Clin. Immunol. 2001, 108:S65-S71.
45. Lin C.C., Tseng H.W., Hsieh H.L., Lee C.W., Wu C.Y., Cheng C.Y., Yang C.M. Tumor necrosis factor-α induces MMP-9 expression via p42/p44 MAPK, JNK, and nuclear factor-κB in A549 cells. Toxicol. Appl. Pharmacol. 2008, 229:386-398.
46. Lee Y.S., Tran H.T.L., Quang V.T. Regulation of expression of matrix metalloproteinase-9 by JNK in Raw 264.7 cells: presence of inhibitory factor(s) suppressing MMP-9 induction in serum and conditioned media. Exp. Mol. Med. 2009, 41:259-268.
47. Liang K.C., Lee C.W., Lin W.N., Lin C.C., Wu C.B., Luo S.F., Yang C.M. Interleukin-1β induces MMP-9 expression via p42/p44 MAPK, p38 MAPK, JNK, and nuclear factor-κB signaling pathways in human tracheal smooth muscle cells. J. Cell. Physiol. 2007, 211:759-770.
48. Hozumi A., Nishimura Y., Nishiuma T., Kotani Y., Yokoyama M. Induction of MMP-9 in normal human bronchial epithelial cells by TNF-α via NF-κB-mediated pathway. Am. J. Physiol. - Lung Cell. Mol. Physiol. 2001, 281:L1444-L1452.
49. Kim D.Y., Park J.W., Jeoung D., Ro J.Y. Celastrol suppresses allergen-induced airway inflammation in a mouse allergic asthma model. Eur. J. Pharmacol. 2009, 612:98-105.
50. Li H., Jia Y.F., Pan Y., Pan D.J., Li D., Zhang L.X. Effect of tripterine on collagen-induced arthritis in rats. Acta Pharmacol. Sin. 1997, 18:270-273.
51. Li H., Zhang Y.Y., Tan H.W., Jia Y.F., Li D. Therapeutic effect of tripterine on adjuvant arthritis in rats. J. Ethnopharmacol. 2008, 118:479-484.
52. Bootsma H., Spronk P.E., Ter Borg E.J., Hummel E.J., De Boer G., Limburg P.C., Kallenberg C.G.M. The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long term observation. Ann. Rheum. Dis. 1997, 56:661-666.
53. Xu X., Wu Z., Xu C., Ren Y., Ge Y. Observation on serum anti-double stranded DNA antibodies of tripterine in systemic lupus erythematosus of (NZBxW)F1 mice. Ann. Rheum. Dis. 2003, 62:377-378.
54. Li H., Zhang Y.Y., Huang X.Y., Sun Y.N., Jia Y.F., Li D. Beneficial effect of tripterine on systemic lupus erythematosus induced by active chromatin in BALB/c mice. Eur. J. Pharmacol. 2005, 512:231-237.
55. Morita T. Celastrol: a new therapeutic potential of traditional chinese medicine. Am. J. Hypertens. 2010, 23:821.
56. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X., Rahmani Z., Krizus A., McKenna-Yasek D., Cayabyab A., Gaston S.M., Berger R., Tanzi R.E., Halperin J.J., Herzfeldt B. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
57. Ripps M.E., Huntley G.W., Hof P.R., Morrison J.H., Gordon J.W. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 1995, 92:689-693.
58. Abou-Raya A., Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun. Rev. 2006, 5:331-337.
59. Kiaei M., Kipiani K., Petri S., Chen J., Calingasan N.Y., Beal M.F. Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegen. Dis. 2006, 2:246-254.
60. Lang A.E., Lozano A.M. Parkinson's disease: second of two parts. New Engl. J. Med. 1998, 339:1130-1143.
61. Faust K., Gehrke S., Yang Y., Yang L., Beal M.F., Lu B. Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease. BMC Neurosci. 2009, 10:109.
62. Cleren C., Calingasan N.Y., Chen J., Beal M.F. Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. J. Neurochem. 2005, 94:995-1004.
63. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 1993, 13:4181-4192.
64. Brouillet E., Condé F., Beal M.F., Hantraye P. Replicating Huntington 's disease phenotype in experimental animals. Prog. Neurobiol. 1999, 59:427-468.
65. Massioui N.E., Ouary S., Chéruel F., Hantraye P., Brouillet E. Perseverative behavior underlying attentional set-shifting deficits in rats chronically treated with the neurotoxin 3-nitropropionic acid. Exp. Neurol. 2001, 172:172-181.
66. Blasko I., Stampfer-Kountchev M., Robatscher P., Veerhuis R., Eikelenboom P., Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer 's disease in old age: the role of microglia and astrocytes. Aging Cell 2004, 3:169-176.
67. Pasinetti G.M. Inflammatory mechanisms in neurodegeneration and Alzheimer 's disease: the role of the complement system. Neurobiol. Aging 1996, 17:707-716.
68. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burgess T., Louis J.C., Collins F., Treanor J., Rogers G., Citron M. β-Secretase cleavage of Alzheimer 's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
69. Paris D., Ganey N.J., Laporte V., Patel N.S., Beaulieu-Abdelahad D., Bachmeier C., March A., Ait-Ghezala G., Mullan M.J. Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer 's disease. J. Neuroinflamm. 2010, 7.
70. Peng B., Xu L., Cao F., Wei T., Yang C., Uzan G., Zhang D. HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way. Mol. Cancer 2010, 9:79.
71. Ge P., Ji X., Ding Y., Wang X., Fu S., Meng F., Jin X., Ling F., Luo Y. Celastrol causes apoptosis and cell cycle arrest in rat glioma cells. Neurol. Res. 2010, 32:94-100.
72. XiaoNan, Wang Q.W., Yang Xu, LianSheng, Zhang Y., Wu C.L. Effects of Celastrol on growth inhibition of U937 leukemia cells through the regulation of the Notch1/NF-kappaB signaling pathway in vitro. Chin. J. Cancer 2010, 29(4):385-390.
73. Idris A.I., Libouban H., Nyangoga H., Landao-Bassonga E., Chappard D., Ralston S.H. Pharmacologic inhibitors of IκB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol. Cancer Ther. 2009, 8:2339-2347.
74. Lu Z., Jin Y., Qiu L., Lai Y., Pan J. Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett. 2009.
75. Morita H., Hirasawa Y., Muto A., Yoshida T., Sekita S., Shirota O. Antimitotic quinoid triterpenes from Maytenus chuchuhuasca. Bioorg. Med. Chem. Lett. 2008, 18:1050-1052.
76. Chen M., Rose A.E., Doudican N., Osman I., Orlow S.J. Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Mol. Cancer Res. 2009, 7:1946-1953.
77. Dai Y., DeSano J.T., Meng Y., Ji Q., Ljungman M., Lawrence T.S., Xu L. Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2009, 74:1217-1225.
78. Pham A.N., Blower P.E., Alvarado O., Ravula R., Gout P.W., Huang Y. Pharmacogenomic approach reveals a role for the x(c)-cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines. J. Pharmacol. Exp. Ther. 2010, 332:949-958.
79. Hightower L.E. Heat shock, stress proteins, chaperones, and proteotoxicity. Cell 1991, 66:191-197.
80. Moseley P.L. Heat shock proteins: a broader perspective. J. Lab. Clin. Med. 1996, 128:233-234.
81. Barišić K., Kopić J. Heat shock proteins and their clinical relevance. Acta Pharm. 2002, 52:71-82.
82. Westerheide S.D., Bosman J.D., Mbadugha B.N.A., Kawahara T.L.A., Matsumoto G., Kim S., Gu W., Devlin J.P., Silverman R.B., Morimoto R.I. Celastrols as inducers of the heat shock response and cytoprotection. J. Biol. Chem. 2004, 279:56053-56060.
83. Kamal A., Boehm M.F., Burrows F.J. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol. Med. 2004, 10:283-290.
84. Hieronymus H., Lamb J., Ross K.N., Peng X.P., Clement C., Rodina A., Nieto M., Du J., Stegmaier K., Raj S.M., Maloney K.N., Clardy J., Hahn W.C., Chiosis G., Golub T.R. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006, 10:321-330.
85. Chadli A., Felts S.J., Wang Q., Sullivan W.P., Botuyan M.V., Fauq A., Ramirez-Alvarado M., Mer G. Celastrol inhibits Hsp90 chaperoning of steroid receptors by inducing fibrillization of the co-chaperone p23. J. Biol. Chem. 2010, 285:4224-4231.
86. Zhang T., Hamza A., Cao X., Wang B., Yu S., Zhan C.G., Sun D. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther. 2008, 7:162-170.
87. Chow A.M., Brown I.R. Induction of heat shock proteins in differentiated human and rodent neurons by celastrol. Cell Stress Chaperones 2007, 12:237-244.
88. Chauhan D., Bianchi G., Anderson K.C. Targeting the UPS as therapy in multiple myeloma. BMC Biochem. 2008, 9.
89. Yang H., Chen D., Qiuzhi C.C., Yuan X., Dou Q.P. Celastrol, a triterpene extracted from the Chinese " Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 2006, 66:4758-4765.
90. Chapelsky S., Batty S., Frost M., Mogride J. Inhibition of anthrax lethal toxin-induced cytolysis of RAW264.7 cells by celastrol. PLoS ONE 2008, 3:e1421.
91. Walcott S.E., Heikkila J.J. Celastrol can inhibit proteasome activity and upregulate the expression of heat shock protein genes, hsp30 and hsp70, in Xenopus laevis A6 cells. Comp. Biochem. Physiol. - Mol. Integr. Physiol. 2010, 156:285-293.
92. Karin M. NF-κB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol. 2009, 1:a000141.
93. Baud V., Karin M. Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 2009, 8:33-40.
94. Sethi G., Sung B., Aggarwal B.B. Nuclear factor-kappaB activation: from bench to bedside. Exp. Biol. Med. (Maywood) 2008, 233:21-31.
95. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006, 441:431-436.
96. Li F., Sethi G. Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. Biochim. Biophys. Acta. 2010, 292:197-207.
97. Wang X.N., Wu Q., Yang X., Zhang L.S., Wu Y.P., Lu C. Effects of Celastrol on growth inhibition of U937 leukemia cells through the regulation of the Notch1/NF-kappaB signaling pathway in vitro. Chin. J. Cancer 2010, 29:385-390.
98. Nagase M., Oto J., Sugiyama S., Yube K., Takaishi Y., Sakato N. Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci. Biotechnol. Biochem. 2003, 67:1883-1887.
99. Hassane D.C., Guzman M.L., Corbett C., Li X., Abboud R., Young F., Liesveld J.L., Carroll M., Jordan C.T. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood 2008, 111:5654-5662.
100. Davenport A., Frezza M., Shen M., Ge Y., Huo C., Chan T.H., Dou Q.P. Celastrol and an EGCG pro-drug exhibit potent chemosensitizing activity in human leukemia cells. Int. J. Mol. Med. 2010, 25:465-470.
101. Jo H., Loison F., Hattori H., Silberstein L.E., Yu H., Luo H.R. Natural product Celastrol destabilizes tubulin heterodimer and facilitates mitotic cell death triggered by microtubule-targeting anti-cancer drugs. PLoS ONE 2010, 5:e10318.
102. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 2000, 103:239-252.
103. Hong Zhu X.-W.L., Cai Tian-Yu, Cao Ji, Tu Chong-Xing, Lu Wei, Qiao-Jun He B.Y. Celastrol acts as a potent anti-metastatic agent targeting β1Integrin and inhibiting cell-ECM adhesion, partially via the p38 MAPK pathway. J. Pharmacol. Exp. Ther. 2010, 334:489-499.
104. Dass C.R., Choong P.F. Cancer angiogenesis: targeting the heel of Achilles. J. Drug Target 2008, 16:449-454.
105. Neuhaus T., Pabst S., Stier S., Weber A.A., Schror K., Sachinidis A., Vetter H., Ko Y.D. Inhibition of the vascular-endothelial growth factor-induced intracellular signaling and mitogenesis of human endothelial cells by epigallocatechin-3 gallate. Eur. J. Pharmacol. 2004, 483:223-227.
106. Zhou Y.X., Huang Y.L. Antiangiogenic effect of celastrol on the growth of human glioma: an in vitro and in vivo study. Chin. Med. J. (Engl) 2009, 122:1666-1673.
107. Lee J.H., Koo T.H., Yoon H., Jung H.S., Jin H.Z., Lee K., Hong Y.S., Lee J.J. Inhibition of NF-κB activation through targeting IκB kinase by celastrol, a quinone methide triterpenoid. Biochem. Pharmacol. 2006, 72:1311-1321.
108. Huang Y., Zhou Y., Fan Y., Zhou D. Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett. 2008, 264:101-106.
109. Blouin S., Baslé M.F., Chappard D. Rat models of bone metastases. Clin. Exp. Metastasis 2005, 22:605-614.
110. Idris A.I., Krishnan M., Simic P., Landao-Bassonga E., Mollat P., Vukicevic S., Ralston S.H. Small molecule inhibitors of I{kappa}B kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy-induced bone loss in vivo. FASEB J. 2010.
111. Westerheide S.D., Bosman J.D., Mbadugha B.N., Kawahara T.L., Matsumoto G., Kim S., Gu W., Devlin J.P., Silverman R.B., Morimoto R.I. Celastrols as inducers of the heat shock response and cytoprotection. J. Biol. Chem. 2004, 279:56053-56060.
112. Abbas S., Bhoumik A., Dahl R., Vasile S., Krajewski S., Cosford N.D., Ronai Z.A. Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin. Cancer Res. 2007, 13:6769-6778.
113. Sun H., Xu L., Yu P., Jiang J., Zhang G., Wang Y. Synthesis and preliminary evaluation of neuroprotection of celastrol analogues in PC12 cells. Bioorg. Med. Chem. Lett. 2010, 20:3844-3847.
114. Peng B., Xu L., Cao F., Wei T., Yang C., Uzan G., Zhang D. HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way. Mol. Cancer 2010, 9:79.
115. He D., Xu Q., Yan M., Zhang P., Zhou X., Zhang Z., Duan W., Zhong L., Ye D., Chen W. The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer 2009, 9:343.
116. Yadav V.R., Sung B., Prasad S., Kannappan R., Cho S.G., Liu M., Chaturvedi M.M., Aggarwal B.B. Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor. J. Mol. Med. 2010.